Skeletal diseases

2020

  • Syngeneic Murine Bladder Cancer Growing in Bone Responds to Anti-PD-1 Treatment at ASBMR Annual Meeting in 2020
  • Chondrogenic Differentiation of Mesenchymal Stem Cell-Like KS483 Cells at ASBMR Annual Meeting in 2020
  • Zoledronate Treatment Improves Trabecular Bone without Affecting Bone Biomechanical Properties in + G610C Mouse Model of Osteogenesis Imperfecta at ASBMR Annual Meeting in 2020

2019

  • Young Adult Male and Female +/G610C Mice as an Animal Model of Osteogenesis Imperfecta at ASBMR Annual Meeting in 2019
  • Effect of Zoledronic Acid Treatment on Bone in +/G610C Mouse Model of Osteogenesis Imperfecta at ASBMR Annual Meeting in 2019
  • Tartrate-Resistant Acid Phosphatase 5b in Rat Serum and Plasma at ASBMR Annual Meeting in 2019

2018

  • Intra-Articular Monosodium IodoacetateInduced Knee Osteoarthritis: Effects on Bone as Measured by Micro-computed Tomography in Rats at ASBMR Annual Meeting in 2018
  • Analgesic Effects of Morphine on Knee Osteoarthritis Induced by Intra-Articular Monosodium Iodoacetatein Rats at ASBMR Annual Meeting in 2018

2017

  • PF708, a therapeutic equivalent and biosimilar candidate to Forteo (teriparatide), demonstrates nonclinical efficacy equivalence to the reference product in the treatment of established osteopenia in adult ovariectomized rats with Pfenex Inc. at the ASBMR Annual Meeting in 2017
  • Suitability of various non-Invasive imaging techniques to analyze bone, muscle and fat tissues in ovariectomized mice with Alizé Pharma III SAS at the ASBMR Annual Meeting in 2017

2016

  • Changes of Articular Cartilage and Subchondral Bone in Rat Osteoarthritis Model Induced by Surgical MMT and MCLT Operation with PreclinApps Ltd at ASBMR Annual Meeting in 2016
  • The Effects of Intra-Articular Treatment with Recombinant Human Bone Morphogenetic Protein 7 (rhBMP-7) on the Development of Post-Traumatic Osteoarthritis in Surgically Induced Rat Models at ASBMR Annual Meeting 2016
  • Changes of Articular Cartilage and Subchondral Bone in Rat Osteoarthritis Model Induced by Surgical MMT and MCLT Operation at ASBMR Annual Meeting 2016
  • Validation of human osteoclast cultures for studying the mode-of-action and identification of new compounds with the potential of inhibiting the vicious cycle in osteolytic bone metastases at AACR Annual Meeting in 2016
  • Differences in the Nature of Osteoarthritis between Surgically and Chemically Induced Rat Models at ORS2016 Annual Meeting

2015

  • The Bone-Protective Effects of a Novel Selective Estrogen Receptor Modulator (pERD) in Ovariectomized Rats with Bayer Healthcare at ASBMR Annual Meeting in 2015
  • The Effects of a Novel Selective Estrogen Receptor Modulator (pERD) on Bone Health in Intact Female Rats with Bayer Healthcare at ASBMR Annual Meeting in 2015
  • Epiphyseal Bone, Subchondral Bone Plate and Epiphyseal Trabecular Bone in Surgically and Chemically Induced Rat Models of Osteoarthritis at ASBMR Annual Meeting in 2015
  • Denosumab and Odanacatib as Reference Compounds in Human Osteoclast Cultures at ASBMR Annual Meeting in 2015
  • Changes in epiphyseal bone, subchondral bone plate and epiphyseal trabecular bone in surgically and chemically induced rat models of osteoarthritis at OARSI World Congress in 2015

2014

  • Intra-Articular Treatment with Recombinant Human Bone Morphogenetic Protein 7 (rhBMP-7) Attenuates the Development of Post-Traumatic Osteoarthritis in Rats at ASBMR Annual Meeting in 2014
  • Characterization of Monosodium Iodoacetate Induced Osteoarthritis in Rat Knee, Including Patellofemoral and Tibiofemoral Joints at ASBMR Annual Meeting in 2014
  • An in Vitro Chondrogenic Differentiation Model Using KS483 Mouse Mesenchymal Progenitor Cell Line with Leiden University Medical Center and Percuros B.V. at ASBMR Annual Meeting in 2014
  • Intra-articular treatment with recombinant human bone morphogenetic protein 7 (BMP-7) attenuates the development of osteoarthritis in a surgically induced rat model at OARSI in 2014

2013

  • Degenerative changes in knee joints as determined by OARSI rat scoring system and osteoarthritis-related joint pain in surgically and chemically induced rat models of osteoarthritis at OARSI in 2013
  • Degenerative Changes in Knee Joints and Joint Pain in Surgically and Chemically Induced Rat Models of Osteoarthritis at ASBMR Annual Meeting in 2013

2012

  • Changes in Bone Turnover Markers by Treatment with Human PTH(1-34) and Zoledronate in Young and Adult Ovariectomized Rats at ASBMR Annual Meeting in 2012
  • Short-Term Effects of Anti-Catabolic and Anabolic Treatments on Bone Turnover Markers in Ovariectomized Rats at ASBMR Annual Meeting in 2012

2010

  • Monitoring of Intermittent PTH(1-34) Treatment by Serum PINP in Adult Ovariectomized Osteopenic Rats with Zealand Pharma at ASBMR Annual Meeting in 2010
  • A Novel Cyclic PTH(1-17) Analog with Bone Anabolic Activity and Efficacy Sufficient to Treat Established Osteopenia in Adult Ovariectomized Rats with Zealand Pharma at ASBMR Annual Meeting in 2010
  • The Novel Selective Androgen Receptor Modulator (SARM) ORM-11984 Prevents the Development of Osteopenia in Aged Orchidectomized Rats with Orion Corporation at ASBMR Annual Meeting in 2010
  • Nanobodies Targeting RANK-Ligand are Strong Inhibitors of Human Osteoclast Differentiation in Vitro with Ablynx at ASBMR Annual Meeting in 2010
  • Sequential treatment with zoledronic acid and doxorubicin has no additive effects in a mouse model of established bone metastases with University of Turku at AACR Annual Meeting in 2010
  • An in Vitro Osteoblast Culture Model Using Estrogen Responsive KS483 Mouse Osteoblast Precursor Cell Line with Percuros B.V. at ECTS in 2010
  • Selective Estrogen Receptor Modulators Increase the Bone Formation Activity of Mouse Osteoblasts in Vitro with Percuros B.V. at ASBMR Annual Meeting in 2010

2009

  • A Novel Selective Androgen Receptor Modulator (SARM) as Monotherapy and Combination Therapy with Alendronate in the Treatment of Established Osteopenia in Orchidectomized Rats with Orion Partners at ASBMR Annual Meeting in 2009
  • The Effects of a Selective Androgen Receptor Modulator (SARM) ORM-11984 on Prevention of Osteoporosis in Rat Immobilization Model with Orion Corporation at ASBMR Annual Meeting in 2009
  • The Effects of a Novel Selective Androgen Receptor Modulator (SARM) ORM-11984 on Prevention of Osteopenia in Ovariectomized Rats with Orion Corporation at ASBMR Annual Meeting in 2009
  • Validation of an in Vitro Osteoblast Culture Model Using Estrogen Responsive KS483 Mouse Osteoblast Precursor Cell Line with Percuros B.V. at ASBMR Annual Meeting in 2009
  • The Effects of Zoledronate in a Treatment Setting in a Nude Mouse Model of Breast Cancer Bone Metastasis at ASBMR Annual Meeting in 2009

2008

  • Changes in Serum PINP in Orchidectomized Osteopenic Rats Treated with PTH and Alendronate with Orion Corporation at ASBMR Annual Meeting in 2008
  • The Ratio of Osteoclast Activity/Osteoclast Number (CTX/TRACP 5b) Is a Useful Parameter in Experimental Rat Models of Osteoporosis with Orion Corporation at ASBMR Annual Meeting in 2008
  • Serum PINP is a Sensitive Marker of Bone Formation in Mouse Ovariectomy Model with Schering AG at ASBMR Annual Meeting in 2008
  • Optimization of Bone Turnover Marker Measurements in a Mouse Model of Glucocorticoid-Induced Osteoporosis at ASBMR Annual Meeting in 2008

2007

  • Effects of 17β-Estradiol and Dihydrotestosterone on Bone Turnover in a Mouse Model of Glucocorticoid-Induced Osteoporosis with Orion Partners at ASBMR Annual Meeting in 2007
  • Serum PINP Is a Useful Marker of Bone Formation in Rat Ovariectomy Model with SBA-Sciences and University of Oulu (Department of Clinical Chemistry) at ASBMR Annual Meeting in 2007
  • A Non-radioactive Immunoassay for Mouse PINP with SBA-Sciences and University of Oulu (Department of Clinical Chemistry) at ASBMR Annual Meeting in 2007

2006

  • Comparison of Oral Dexamethasone and Prednisolone in a Mouse Model of Glucocorticoid-Induced Osteoporosis with Schering AG at ASBMR Annual Meeting in 2006

2005

  • The Ratio of Osteoclast Activity/Osteoclast Number (CTX/TRACP 5b) Improves the Interpretation of the Effects of Anti-Resorptive Treatment in Human Osteoclast Cultures with Organon Laboratories at ASBMR Annual Meeting in 2005
  • The Ratio of Osteoclast Activity/Osteoclast Number (CTX/TRACP 5b) is a Useful Parameter in Rat Orchidectomy Model with Orion Pharma at ASBMR Annual Meeting in 2005

2003

  • Development and Characterization of a Novel Human In Vitro Bone Resorption Assay Useful For Preclinical Testing of Osteoporosis Drug Candidates with University of Turku at ASBMR Annual Meeting in 2003